A use case of the benign HLA-Ligand-Atlas is the prioritization of tumor-associated targets for e.g. peptide vaccination. Based on three glioblastoma samples, we illustrated how many of these peptides are covered in the benign dataset. The experimental and computational workflow for the isolation and identification of the glioblastoma immunopeptidomes is the same, as for all samples included in the HLA Ligand Atlas. As the three glioblastoma samples are not included in the HLA Ligand Atlas dataset, they have been deposited under a separate submission.
[dataset license: CC0 1.0 Universal (CC0 1.0)]
Keywords: Human ; Hla ; Glioblastoma ; Immunopeptidomics ; DatasetType:Proteomics
|
Principal Investigators: (in alphabetical order) |
Hans-Georg Rammensee, Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University T�bingen, N/A |
| Submitting User: | ccms |
| Number of Files: | |
| Total Size: | |
| Spectra: | |
| Subscribers: | |
| Owner | Reanalyses | |
|---|---|---|
| Experimental Design | ||
|
Conditions:
|
||
|
Biological Replicates:
|
||
|
Technical Replicates:
|
||
| Identification Results | ||
|
Proteins (Human, Remapped):
|
||
|
Proteins (Reported):
|
||
|
Peptides:
|
||
|
Variant Peptides:
|
||
|
PSMs:
|
||
| Quantification Results | ||
|
Differential Proteins:
|
||
|
Quantified Proteins:
|
||
| Browse Dataset Files | Browse Results |
|
FTP Download Link (click to copy):
|
|